Investor Letter - H2 2020Disruptive innovation, evolution of the digital economy, asset bubbles, new positions in GoodRx, Roku and Teladoc and selling Dropbox.
Investor Letter - Q2 2020The theory of market outperformance, the biology of investing, where market inefficiencies have transpired, and a portfolio update.
Investor Letter - Q1 2020Investing versus speculating, timing the market, holding cash, and investing opportunity costs, stocks versus bonds.
Investor Letter - Q3 2019Management fees, is value investing dead, evolution of a value investor, and compounders and fair valuation.